Abstract
Pharmaceutical aerosols comprise a wide range of drug products which all are dispersed as droplets (wet aerosol) or particles (dry aerosol) in a gas for application. Hence, the device being used for dispersion plays a very important role as it impacts the dispersion efficiency and significantly influences the resulting aerosol particle size. For an aerosol’s therapeutic effect it is important how the particles behave in the gas they are dispersed in, i.e. how they distribute and deposit. Therefore, aerodynamic particle size is important in addition to a geometrical particle size—unlike many other formulations where only geometrical particle size is looked at. The chapter defines the differences in particle sizes and gives an overview of measurement techniques to determine aerodynamic particle size as well as other sizing techniques in use for aerosol particle sizing. Pharmacopoeial requirements are summarized and physiological implications as well as ideas to closer mimic the in vivo situation are discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Byron PR, Hindle M, Lange CF, Longest PW, McRobbie D, Oldham MJ, Olsson B, Thiel CG, Wachtel H, Finlay WH (2010) In vivo–in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. J Aerosol Med Pulm Drug Delivery 23:S59–S69
Byron PR, Wei X, Delvadia RR, Longest PW (2013) Standardizing in vitro test methods to support aerosol drug evaluation in the clinic. Respir Drug Deliv 1:85–92
Carvalho TC, Peters JI, Williams RO III (2011) Influence of particle size on regional lung deposition—what evidence is there? Int J Pharm 406:1–10
de Backer J (2012) Novel imaging in assessing small airway disease and therapy. In: Proceedings of DDL 23. Edinburgh, Scotland
de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW (2002) Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. Int J Pharm 249:219–231
Dekati (2010) Dekati ELPI: electrical low pressure impactor. Tampere
Glover W, Chan H-K (2004) Electrostatic charge characterization of pharmaceutical aerosols using electrical low-pressure impaction (ELPI). Aerosol Sci 35:755–764
Heim M, Mullins BJ, Umhauer H, Kasper G (2008) Performance evaluation of three optical particle counters with an efficient "multimodal" calibration method. J Aerosol Sci 39:1019–1031
Hickey AJ, Martonen TB, Yang Y (1996) Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols. Pharm Acta Helv 71(3):185–190
Hinds WC (1999) Aerosol technology—properties, behavior and measurement of airborne particles. John Wiley & Sons
Hoe S, Young PM, Chan H-K, Traini D (2009) Introduction of the electrical next generation impactor (eNGI) and investigation of its capabilities for the study of pressurized metered dose inhalers. Pharm Res 26(2):431–437
Kippax P, Fracassi J (2003) Particle size characterisation in nasal sprays and aerosols. LabPlus International
Kotian R, Peart J, Bryner J, Byron PR (2009) Calibration of the modified electrical low-pressure impactor (ELPI) for use with pressurized pharmaceutical aerosols. J Aerosol Med Pulm Drug Deliv 22(1):55–66
Marjamäki M, Keskinen J, Chen D-R, Pui DYH (2000) Performance evaluation of the electrical low-pressure impactor (ELPI). J Aerosol Sci 31(2):249–261
Marple VA, Olson BA, Santhanakrishnan K, Mitchell JP, Murray SC, Hudson-Curtis BL (2003a) Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part II: archival calibration. J Aerosol Med 16(3):301–324
Marple VA, Roberts DL, Romay FJ, Miller NC, Truman KG, Van Oort M, Olsson B, Holroyd MJ, Mitchell JP, Hochrainer D (2003b) Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: design. J Aerosol Med 16(3):283–299
Marple VA, Olson BA, Santhanakrishnan K, Roberts DL, Mitchell JP, Hudson-Curtis BL (2004) Next generation pharmaceutical impactor: a New impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L/min. J Aerosol Med 17(4):335–343
Mitchell JP, Nagel MW (1999) Time-of-flight aerodynamic particle size analyzers: their use and limitations for the evaluation of medical aerosols. J Aerosol Med 12(4):217–240
Olsson B, Borgström L, Lundbäck H, Svensson M (2013) Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products. J Aerosol Med Pulm Drug Delivery 26(6):355–369
Stapleton KW, Guentsch E, Hoskinson MK, Finlay WH (2000) On the suitability of k–ε turbulence modeling for aerosol deposition in the mouth and throat: a comparison with experiment. J Aerosol Sci 31(6):739–749
Steckel H, Bolzen N (2004) Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm 270(1–2):297–306
Stein SW, Myrdal PB, Gabrio BJ, Obereit D, Beck TJ (2003) Evaluation of a new aerodynamic particle sizer spectrometer for size distribution measurements of solution metered dose inhalers. J Aerosol Med 16(2):107–119
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Controlled Release Society
About this chapter
Cite this chapter
Scherließ, R. (2016). Particle Size Measurements in Aerosols. In: Müllertz, A., Perrie, Y., Rades, T. (eds) Analytical Techniques in the Pharmaceutical Sciences. Advances in Delivery Science and Technology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-4029-5_22
Download citation
DOI: https://doi.org/10.1007/978-1-4939-4029-5_22
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-4027-1
Online ISBN: 978-1-4939-4029-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)